Predicate Devices and Medical Device Standards: A Guide for Manufacturers

Manufacturers must navigate complex approval processes across different global markets. A central concept in many regulatory pathways is the use of predicate devices.

Understanding how to effectively leverage predicate devices and adhere to applicable medical device standards is essential for streamlining submissions and gaining market access efficiently.

This guide explores what predicate devices are, how they’re used in major regulatory regions, the role of standards in these processes, and how technology is transforming predicate selection and submission preparation. In addition to predicate devices, adherence to international standards helps demonstrate compliance with essential safety and performance requirements.

A key 2026 development for U.S.-market manufacturers is the QMSR (Quality Management System Regulation), which took effect February 2, 2026, aligning FDA’s quality system requirements under 21 CFR Part 820 with ISO 13485:2016. For manufacturers operating globally, aligning product development and documentation with updated international standards has never been more important for regulatory acceptance.

Understanding Predicate Devices in the Regulatory Landscape

A predicate device is a previously approved medical device that serves as a benchmark to demonstrate that a new device is substantially equivalent in terms of safety and effectiveness. This concept is especially relevant in the FDA 510(k) process but has equivalents in other regulatory jurisdictions.

The rationale is straightforward: if a new device is shown to be similar to a legally marketed device, the regulatory burden can be reduced. This process expedites access to the market while also maintaining public safety.

In addition to predicate devices, adherence to international standards (such as those developed by ISO, IEC, or the GHTF) helps demonstrate compliance with essential safety and performance requirements. Aligning product development and documentation with these standards enhances regulatory acceptance and reduces review time.

In September 2023, the FDA issued draft guidance on best practices for selecting a predicate device in 510(k) submissions. The guidance recommends selecting a predicate that was cleared using well-established methods, meets or exceeds expected safety and performance standards, has no unmitigated use-related or design-related safety issues, and has no associated design-related recalls.

While still in draft form, manufacturers pursuing 510(k) submissions should factor these best practices into their predicate selection strategy, as FDA reviewers are increasingly applying this lens.

What is a Predicate Device?

A predicate device helps determine whether a new device can follow a streamlined regulatory pathway. In the U.S., a 510(k) submission requires the manufacturer to prove substantial equivalence to a predicate, meaning:

• The same intended use
• Similar or same technological characteristics
• Or, if different, that any changes do not raise new questions of safety or effectiveness

Manufacturers must provide clear evidence, including comparative data, technical documentation, and possibly benches or clinical studies, depending on the risk level. Globally, the predicate device definitions carry slightly, but the general concept is the same: reduce redundant evaluation by comparing new products to existing, approved ones.

Understanding how predicate devices relate to regulatory compliance for medical devices is foundational to creating an effective global regulatory strategy.

Global Overview: Predicate Pathways by Region

FDA 510(k) Process (United States)

In the U.S., the 510(k) pathway remains one of the most widely used methods for market entry.

There are three types of 510(k) submissions:

1. Traditional 510(k): A full comparison to a predicate device.
2. Special 510(k): For modifications made by the original manufacturer.
3. Abbreviated 510(k): Leverages consensus standards and guidance.

Substantial equivalence (SE) is the core requirement, manufacturers must provide evidence that their device matches or improves upon a predicate device without compromising safety or efficacy. Standards like IEC 60601, ISO 14971, and ISO 10993 often support the safety and performance claims, enabling a faster FDA review.

As of February 2, 2026, the FDA’s QMSR took effect, requiring manufacturers to align their quality management systems with ISO 13485:2016. For 510(k) submissions, QMS compliance is now a prerequisite reviewers actively examine; clearance may be withheld if QMS failures pose a serious risk.

For manufacturers of AI-enabled devices, the FDA finalized Predetermined Change Control Plans (PCCPs) guidance in December 2024. PCCPs allow manufacturers to pre-specify and pre-authorize certain iterative software modifications (including AI/ML model updates) without requiring a new 510(k) submission for each change. Importantly, if a predicate device had an authorized PCCP, the substantial equivalence comparison is made to the predicate before its PCCP-implemented changes.

Manufacturers should also be aware that FDA workforce reductions in 2025 have raised questions about sustained review capacity, with approximately 180 CDRH employees dismissed. Rising submission volumes, approximately 21,700 510(k) submissions in FY2025, mean that well-prepared, clearly documented submissions are more important than ever for avoiding delays.

MDR and Equivalence Claims (European Union)

Under the EU MDR (Medical Device Regulation), manufacturers cannot rely on predicate devices in the same way as the U.S. Instead, equivalence claims are made under Article 61 during clinical evaluation.

Three core criteria must be met:

1. Same clinical condition and intended purpose
2. Similar technology
3. Equivalent performance and safety

Unlike the FDA, the EU requires access to technical documentation for the device being referenced, making it challenging for third-party equivalence claims. However, using harmonized standards supports conformity with essential MDR requirements.

The December 2025 European Commission proposal to simplify MDR/IVDR rules introduces meaningful changes to the equivalence framework. The conditions for relying on clinical data of an equivalent device are proposed to be made more flexible, and the possibility of demonstrating a device’s safety and performance based on non-clinical data alone is being expanded under Article 61. A new definition of “well-established technology device” is also proposed, which would subject eligible devices to more proportionate clinical evidence requirements.

MDCG 2023-7, published December 2023, provides guidance on exemptions from the requirement to perform clinical investigations under Article 61(4)–(6) MDR and clarifies what constitutes “sufficient levels of access” to data needed to justify equivalence claims. Manufacturers relying on equivalence should reference this guidance alongside MDCG 2020-5 when building their clinical evaluation strategy.

Note: the December 2025 proposals have not yet been adopted; current MDR rules remain fully in effect. The Commission anticipates co-legislator adoption no earlier than Q2 2027. Manufacturers should monitor progress while complying with current requirements.

Health Canada’s Framework (Canada)

Health Canada also considers predicate-like submissions, especially for Class III and IV medical devices. These pathways are not identical to the U.S. 510(k) process but still allow manufacturers to use comparative evidence from similar marketed devices to reduce regulatory burden.

Manufacturers must align with recognized standards, such as CAN/CSA or international equivalents, to prove safety and effectiveness.

Health Canada also considers predicate-like submissions, especially for Class III and IV medical devices. Manufacturers may use comparative evidence from similar marketed devices to reduce regulatory burden.

Canada’s regulatory landscape is actively evolving: the Agile Licensing Regulations took effect January 1, 2026, introducing terms and conditions for Class II, III, and IV medical devices, and a second phase of Medical Devices Regulations amendments is currently underway. Manufacturers using comparative pathways in Canada should ensure their submissions are aligned with the most current Health Canada guidance, including the March 2026 final guidance on significant changes to Class III and IV devices.

TGA Conformity Assessment (Australia)

Australia’s TGA (Therapeutic Goods Administration) requires manufacturers to meet Essential Principles for safety and performance, often supported by standards and clinical evidence. Predicate devices can be referenced in clinical evaluations, especially when used to justify the absence of new clinical trials.

Australia’s TGA requires manufacturers to meet Essential Principles for safety and performance, often supported by standards and clinical evidence. Predicate devices can be referenced in clinical evaluations. In 2026, sponsors of Class III and Class IIb medical devices face new TGA compliance requirements, with UDI requirements for lower-risk Class IIa devices and IVDs to follow.

Manufacturers referencing predicate-like evidence in TGA submissions should ensure their clinical evaluation documentation accounts for these updated compliance expectations.

Other Key Markets (Brazil, Japan, and China)

• Brazil (ANVISA): ANVISA’s 2025 manual for health-use materials registration has standardized requirements for medical device submissions, aligned with RDC 751/2022. Manufacturers and importers can reduce errors and accelerate approvals by aligning with the updated manual.
• Japan (PMDA): Still requires extensive documentation in Japanese, with local predicate referencing permitted. Japan’s participation in MDSAP continues to facilitate some harmonization with other markets.
• China (NMPA): Stricter local clinical data requirements persist, with limited acceptance of foreign predicates. Manufacturers should plan for NMPA-specific clinical evaluation strategies rather than assuming cross-market predicate acceptance.

Manufacturers must align with local technical standards while leveraging equivalence when possible.

The Role of Standards and Guidance Documents

Medical device standards provide a consistent framework for proving safety and performance. Whether you’re referencing ISO 13485 for quality systems or IEC 60601 for electrical safety, aligning with international medical device standards can support claims of equivalence and simplify global submissions.

Key advantages of using standards include:

ISO 13485 (quality management systems, now aligned with QMSR in the U.S. as of February 2026), IEC 60601 (electrical safety for active medical devices), ISO 14971 (risk management), and ISO 10993 (biocompatibility). The FDA’s 2023 draft guidance on predicate selection also explicitly references the importance of standards compliance as a factor in assessing whether a predicate device remains an appropriate benchmark; devices cleared using outdated methods or with safety issues may no longer represent a sound foundation for a new submission.

In many regions, referencing recognized or harmonized standards offers a presumption of conformity, making your regulatory review more straightforward.

Selecting the Right Predicate Device

Choosing the right predicate device is a key step in any regulatory submission. A poor match can delay approval or result in rejection.

The FDA’s 2023 Best Practices draft guidance recommends selecting predicates that were cleared using well-established methods, meet or exceed current safety and performance expectations, have no unmitigated design-related safety issues, and have no associated design-related recalls. FDA acknowledges that older predicate devices (particularly those over 10 years old) may rely on outdated technology and face increased scrutiny.

Selecting a more recently cleared predicate is generally advisable, and the FDA has signaled that predicate lineage, including recall history, will receive increasing attention. Use FDA’s 510(k) database to identify appropriate candidates and cross-reference the device’s recall history before finalizing your selection.

Small differences can raise new safety concerns, potentially requiring additional clinical data. A careful, strategic selection helps streamline the review process and improves your chances of success.

Key Considerations for Manufacturers Using Predicate Devices Globally

When developing a global regulatory submission strategy, keep in mind:

• Not all jurisdictions accept U.S. predicate logic
• Documentation access (especially in the EU) can be restrictive
• Clinical evidence requirements vary so plan for data reuse across markets
• Avoid assumptions because predicate acceptance in one country doesn’t mean automatic approval in another.
• Understand MDR codes

Global alignment requires careful planning and coordination of clinical, technical, and regulatory documents.

How Technology Can Help

Technology is playing a growing role in simplifying regulatory processes for medical device manufacturers. AI-driven tools and regulatory intelligence platforms are making it easier to identify suitable predicate devices and prepare stronger submissions.

The FDA’s January 2025 draft guidance on AI-enabled device software functions highlights the importance of lifecycle management and transparency in AI-based submissions; including how AI tools used in regulatory workflows themselves must be validated and governed. For manufacturers of AI-enabled devices, technology is not just a submission aid but also part of the regulatory subject matter, requiring careful integration of PCCP planning, cybersecurity documentation, and AI lifecycle governance alongside traditional predicate strategy.

Conclusion

Predicate device strategy in 2026 demands more than a database search and a comparison table. From FDA’s new best-practice criteria for predicate selection and the QMSR quality system alignment, to the EU’s proposed flexibility in Article 61 equivalence claims and tightening TGA compliance deadlines, the global landscape is shifting rapidly.

Manufacturers who build a proactive, market-specific submission strategy, grounded in current standards, updated guidance, and the right technology tools, will be best positioned to achieve faster approvals and sustained market access.

Q&A:

1. What is a predicate device and why does it matter for regulatory submissions? A predicate device is a previously approved medical device that serves as a benchmark to demonstrate that a new device is substantially equivalent in terms of safety and effectiveness. The rationale is straightforward: if a new device is shown to be similar to a legally marketed device, the regulatory burden can be reduced, expediting market access while maintaining public safety. This concept is most prominent in the FDA 510(k) process but has equivalents in other regulatory jurisdictions around the world.
2. What are the three types of 510(k) submissions in the U.S.? The three types are the Traditional 510(k), which involves a full comparison to a predicate device; the Special 510(k), which is used for modifications made by the original manufacturer; and the Abbreviated 510(k), which leverages consensus standards and FDA guidance documents. In all three cases, substantial equivalence to a predicate is the core requirement, and standards such as IEC 60601, ISO 14971, and ISO 10993 are commonly used to support safety and performance claims.
3. What does the FDA’s 2023 draft guidance recommend when selecting a predicate device? The FDA’s 2023 draft guidance on best practices for predicate selection recommends choosing a predicate that was cleared using well-established methods, meets or exceeds current safety and performance expectations, has no unmitigated use-related or design-related safety issues, and has no associated design-related recalls. The FDA has also signaled that older predicate devices (particularly those over 10 years old) may rely on outdated technology and face increased scrutiny, making more recently cleared predicates generally the safer choice.
4. How did the FDA’s QMSR change things for 510(k) submissions as of 2026? The FDA’s Quality Management System Regulation (QMSR) took effect on February 2, 2026, aligning the FDA’s quality system requirements under 21 CFR Part 820 with ISO 13485:2016. For 510(k) submissions, QMS compliance is now a prerequisite that reviewers actively examine, clearance may be withheld if QMS failures pose a serious risk. For manufacturers operating globally, this alignment makes it more important than ever to ensure product development and documentation are consistent with updated international standards.
5. How does the EU MDR approach equivalence differently from the FDA’s 510(k) process? Under the EU MDR, manufacturers cannot rely on predicate devices in the same way as in the U.S. Instead, equivalence claims are made under Article 61 during clinical evaluation, and three core criteria must be met: the same clinical condition and intended purpose, similar technology, and equivalent performance and safety. A key difference is that the EU requires access to the technical documentation of the device being referenced, which makes third-party equivalence claims particularly challenging. Using harmonized standards helps support conformity with essential MDR requirements.
6. Are there proposed changes to the EU MDR equivalence framework manufacturers should be aware of? Yes. A December 2025 European Commission proposal to simplify MDR/IVDR rules includes meaningful changes to the equivalence framework. The conditions for relying on clinical data from an equivalent device are proposed to be more flexible, and the possibility of demonstrating safety and performance based on non-clinical data alone is being expanded under Article 61. A new definition of “well-established technology device” is also proposed, which would subject eligible devices to more proportionate clinical evidence requirements. However, these proposals have not yet been adopted, current MDR rules remain fully in effect, with co-legislator adoption anticipated no earlier than Q2 2027.
7. How do Canada and Australia approach predicate-like pathways? Health Canada allows manufacturers of Class III and IV medical devices to use comparative evidence from similar marketed devices to reduce regulatory burden, similar in principle to the U.S. 510(k) approach. Canada’s regulatory landscape is actively evolving, with the Agile Licensing Regulations taking effect January 1, 2026, and a second phase of Medical Devices Regulations amendments currently underway. In Australia, the TGA requires manufacturers to meet Essential Principles for safety and performance, and predicate devices can be referenced in clinical evaluations, particularly to justify the absence of new clinical trials. In 2026, sponsors of Class III and Class IIb devices face new TGA compliance requirements, with UDI obligations for lower-risk devices to follow.
8. What should manufacturers know about using predicates in Brazil, Japan, and China? Each market has distinct requirements. In Brazil, ANVISA’s 2025 manual for health-use materials registration has standardized submission requirements aligned with RDC 751/2022, and following the updated manual can reduce errors and accelerate approvals. In Japan, the PMDA permits local predicate referencing but still requires extensive documentation in Japanese; Japan’s participation in MDSAP facilitates some harmonization with other markets. In China, the NMPA maintains stricter local clinical data requirements with limited acceptance of foreign predicates, so manufacturers should plan NMPA-specific clinical evaluation strategies rather than assuming cross-market predicate acceptance.
9. What role do international standards play in predicate device strategies? International standards provide a consistent framework for demonstrating safety and performance across markets. Key standards include ISO 13485 for quality management systems, IEC 60601 for electrical safety, ISO 14971 for risk management, and ISO 10993 for biocompatibility. In many regions, referencing recognized or harmonized standards offers a presumption of conformity, making regulatory reviews more straightforward. The FDA’s 2023 draft guidance on predicate selection also explicitly references standards compliance as a factor when assessing whether a predicate remains an appropriate benchmark.
10. What are the key pitfalls to avoid when building a global predicate device strategy? Several common mistakes can delay or derail submissions across markets. Assuming that predicate acceptance in one country translates to automatic approval in another is a significant risk; not all jurisdictions accept U.S. predicate logic. Documentation access in the EU can be highly restrictive, particularly for third-party equivalence claims. Clinical evidence requirements vary widely, so planning for data reuse across markets from the outset is essential. Manufacturers should also ensure their predicate’s recall history has been thoroughly checked, as the FDA is placing increasing scrutiny on predicate lineage. Careful, market-specific planning and coordination of clinical, technical, and regulatory documents is the foundation of a successful global strategy.